MonoRabᵀᴹ Rabbit Anti-Camelid VHH Monoclonal Antibody Series
Camelids naturally produce antibodies composed only of heavy chains as compared to the conventional antibodies (Fig 1)The antigen-binding site of these unusual heavy chain antibodies is formed only by a single heavy chain variable domain, designated as single domain antibodies (sdAbs or VHHs). Because of their unique structure, small size and stability, VHHs have several advantages comparing to conventional antibodies or their fragments. Several VHHs are now being studied for use in the diagnostic ﬁelds and therapeutic areas, including oncology, infectious, inflammatory, and neurodegenerative diseases.
Rabbit anti-camelid VHH monoclonal antibody series generated by Genscript's proprietary rabbit-mouse hetero-hybridoma technology MonoRab™ provide perfect secondary antibody tools for researchers to identify target-speciﬁc sdAbs. Unconjugated, HRP, iFluor488 and iFluor555 conjugates are available.
- MonoRab™ technology guarantees high affinity: Kd ≈ 10-11 M
- No cross reactivity with other species
- Recognizes the variable domain of camelid (Llama and Camel) antibodies
- Specific to camelid IgG2 & IgG3
- Recognizes conformational epitope
Conventional polyclonal antibodies recognize many epitopes, leading to high background and cross reactivity in many assays. M205 is specific to native rabbit IgG and doesn't react with denatured or reduced rabbit IgG heavy or light chain.
It's an ideal tool for Immunoprecipitation and Western blot. Primary antibody heavy and light chain contamination can be avoided.
High sensitivity and low background
The result demonstrates that Anti-Rabbit IgG Monoclonal Secondary Antibody (M205) provides less background noise than conventional polyclonal
secondary antibody with equivalent sensitivity.
Binding to conserved epitope
Detection of different titrated primary rabbit antibodies using
Anti-Rabbit IgG Monoclonal Secondary Antibody (M205) (HRP
conjugate) #A1827 indicates that M205 binds to a conserved rabbit
IgG epitope, and can recognize primary antibodies generated from